LiDCO Group Plc Appointment of Head of North America

TIDMLID

LiDCO Group Plc

10 January 2017

LIDCO GROUP PLC

("LiDCO" or the "Company" or the "Group")

Appointment of Head of North America

LiDCO (AIM: LID), the hemodynamic monitoring company, announces the appointment of Shane Doorish, as Head of North America, with immediate effect.

Shane brings with him 19 years of experience in the healthcare sector having originally trained as a critical care nurse. This includes 12 years with Edwards Lifesciences, a major global provider of hemodynamic monitoring, where Shane held a number of sales and marketing positions. Shane's last role with Edwards Lifesciences was as Managing Director of Canada. Importantly for LiDCO, Shane has an in depth knowledge of the hemodynamic market and is well placed to be able to drive the Company's expansion plans in North America.

In December 2016, LiDCO announced that it had raised gross funds of GBP3.0 million, through a Placing and Subscription, to provide growth capital to enable the Company to expand its global sales team and undertake a more extensive and focused marketing effort.

Commenting on the appointment, Matt Sassone, Chief Executive Officer of LiDCO, said: "I am very pleased to have Shane joining the team, this is an important step in our expansion plans for North America. His knowledge of the market and commercial skills are ideal to execute on LiDCO's plans to drive greater revenues from the world's largest hemodynamic market."

 
 LiDCO Group Plc                                            www.lidco.com 
 Matt Sassone (CEO)                              Tel: [phone] 
 Paul Clifford (Finance 
  Director) 
 
 finnCap Ltd                                     Tel: [phone] 
 Geoff Nash / Emily Watts 
  (Corporate Finance) 
 Stephen Norcross (Corporate 
  Broking) 
 
 Walbrook PR Ltd               Tel: [phone] or [e-mail] 
 Paul McManus                                          Mob: [phone] 
 Lianne Cawthorne                                      Mob: [phone] 
 

About LiDCO Group Plc (www.lidco.com)

LiDCO is a supplier of non-invasive and minimally invasive hemodynamic equipment to hospitals used to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the application of hemodynamic optimisation protocols for high risk patients in both critical care units and in the operating theatre.

Increasingly clinical studies are showing that the optimisation of patients' hemodynamic status in high risk patients produces better outcomes and reduced hospital stay. LiDCO's computer-based technology, developed at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.

Key Products:

LiDCOunity: a hemodynamic monitor that combines the full suite of LiDCO technology (non-invasive, minimally invasive and calibrated technologies) into one platform. Designed to have the flexibility to adapt to a patient's changing acuity, the product enables clinicians to seamlessly transition between non-invasive, minimally invasive and calibrated hemodynamic monitoring.

LiDCOplus: a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%).

LiDCOrapid: a cardiac output monitor designed specifically for use in the operating theatre for fluid and drug management. The monitor enables anaesthetists to receive accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being before, during and after surgery. The LiDCOrapid provides:

-- early and rapid warning of hemodynamic change to aid choice of therapeutic route: fluid or drug

-- quantification of hemodynamic response guidance on effective delivery of fluids to ensure the right amount at the right time

The software incorporated into LiDCOrapid allows the LiDCOrapid monitor to co-display Medtronic's level of consciousness parameter ('BIS(TM') )* and add the convenience of CNSystem's continuous non-invasive blood pressure monitoring ('CNAP')**. This addresses a growing requirement for non-invasive monitoring solutions that are more comprehensive and can effectively replace multiple single parameter monitors.

LiDCOview: an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data.

*BIS(TM) and Bispectral Index are trademarks of Medtronic registered in the US and foreign countries.

**CNAP(TM) is a trademark of CNSystems Medizintechnik AG.

LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream.

LiDCO Distribution Network:

LiDCO sells directly to hospitals in the UK and USA and through a network of specialty critical care and anaesthesia distributors in the rest of the world.

LiDCO's headquarters are in London and its shares are traded on AIM.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAUKVBRBAAARAR

(END) Dow Jones Newswires

January 10, 2017 02:00 ET (07:00 GMT)